Home » NDRS » Page 4 P47 Treatment pathways of patients diagnosed with hepatocellular carcinoma (HCC) after initial locoregional treatment in England Amy Zalin-Miller, Sophie Jose, Sophia Le Mare, Betina Blak T https://gut.bmj.com/content/72/Suppl_3/A42.2 Background ...
Home » NDRS » Page 4 Wills, L., Nagarwalla, D., Pearson, C. et al. Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis. Eur J Health Econ (2023). https://doi.org/10.1007/s10198-023-01623-5...
Home » NDRS » Page 4 Mahmoudpour SH, Knott CS, Amin A, Boutmy E, Verpillat P. Integration of Immuno-oncology (IO) Treatments into Routine Clinical Practice for the Treatment of Patients with Advanced or Metastatic Cancers: Analysis of the England National Cancer...
Home » NDRS » Page 4 Goulden S, Heffernan K, Sen Nikitas F, et al. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England....
Home » NDRS » Page 4 Gannon MR, Dodwell D, Miller K, Horgan K, Clements K, Medina J, et al.Cancer Epidemiology, Volume 86, 2023 https://doi.org/10.1016/j.canep.2023.102423 Abstract Background Endocrine therapy (ET) is a widely used treatment for breast cancer. In the...
